Demystifying the Global Health Workforce

 

In the latest episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims, Chief Marketing & Communications Officer at TruMerit (formerly CGFNS International, Inc.), is joined by Jim Campbell, Director of Health Workforce at the World Health Organization (WHO), and Peter Preziosi, President & CEO of TruMerit. Together, they explore pressing global nursing workforce challenges, the upcoming State of the World’s Nursing Report, and strategies for strengthening health systems worldwide.

Jim Campbell highlights the WHO Global Strategy on Health Workforce 2030, emphasizing the need for investment in workforce education, optimizing existing resources, and improving global workforce data to ensure universal health coverage. He also discusses the impact of COVID-19, which accelerated innovation in digital health and workforce policies but also exposed critical shortages and funding gaps.

Peter Preziosi introduces True Merit’s focus on care model evolution, ethical recruitment, and career mobility. He shares insights on their initiatives, including a global rehabilitation certification for nurses and the evaluation of ethical recruitment standards to align with WHO’s Global Code of Practice on International Recruitment. Both guests stress the urgency of addressing workforce shortages, ensuring fair recruitment practices, and adapting education to prepare healthcare professionals for the future.

As the healthcare landscape evolves, this episode underscores the importance of global collaboration, policy innovation, and investment in nursing leadership to sustain a resilient workforce.

Tune in to the full episode at trumerit.org/podcast or on your favorite podcast platform.

Follow Along For More Episodes!

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…